Kenneth Hoberman
2018
In 2018, Kenneth Hoberman earned a total compensation of $7.5M as Chief Operating Officer at Stemline Therapeutics, a 303% increase compared to previous year.
Compensation breakdown
| Bonus | $359,225 |
|---|---|
| Non-Equity Incentive Plan | $930,004 |
| Salary | $478,966 |
| Stock Awards | $5,774,833 |
| Total | $7,543,028 |
Hoberman received $5.8M in stock awards, accounting for 77% of the total pay in 2018.
Hoberman also received $359.2K in bonus, $930K in non-equity incentive plan and $479K in salary.
Rankings
In 2018, Kenneth Hoberman's compensation ranked 1,102nd out of 14,244 executives tracked by ExecPay. In other words, Hoberman earned more than 92.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,102 out of 14,244 | 92nd |
Division Manufacturing | 373 out of 5,765 | 94th |
Major group Chemicals And Allied Products | 116 out of 2,128 | 95th |
Industry group Drugs | 89 out of 1,817 | 95th |
Industry Pharmaceutical Preparations | 63 out of 1,391 | 96th |
Source: SEC filing on April 30, 2019.
Hoberman's colleagues
We found two more compensation records of executives who worked with Kenneth Hoberman at Stemline Therapeutics in 2018.